サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1551743

帯状疱疹ワクチンの世界市場

Shingles Vaccines

出版日
ページ情報
英文 269 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.82円
帯状疱疹ワクチンの世界市場
出版日: 2024年09月10日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 269 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

帯状疱疹ワクチンの世界市場は2030年までに45億米ドルに達する見込み

2023年に32億米ドルと推定される帯状疱疹ワクチンの世界市場は、2023～2030年の分析期間にCAGR 5.0%で成長し、2030年には45億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである組み換えワクチンは、CAGR 5.1%を記録し、分析期間終了時には39億米ドルに達すると予測されます。弱毒化ワクチン分野の成長率はCAGR 4.2%と推定されます。

米国市場は推定8億6,860万米ドル、中国はCAGR 8.2%で成長予測

米国の帯状疱疹ワクチン市場は、2023年に8億6,860万米ドルと推定されます。世界第2位の経済大国である中国は、2023-2030年のCAGRを8.2%として、2030年までに9億2,820万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.9%と5.2%と予測されています。欧州では、ドイツがCAGR 3.0%で成長すると予測されています。

世界の帯状疱疹ワクチン市場- 主要動向と促進要因のまとめ

帯状疱疹ワクチンの仕組みと主な構成要素は？

帯状疱疹ワクチンは帯状疱疹、一般的に帯状疱疹として知られる、水痘と同じ水痘帯状疱疹ウイルスの再活性化によって引き起こされる痛みを伴うウイルス感染症から身を守るためにデザインされた重要な予防ツールです。一度水疱瘡にかかると、ウイルスは体内で休眠状態にあり、特に高齢者や免疫力の低下した人では、後年帯状疱疹として再活性化する可能性があります。帯状疱疹ワクチンは、ウイルスに対する身体の免疫反応を高めることで、再活性化の可能性を減らし、万が一発症した場合の症状の重さを軽減します。これらのワクチンの主要成分には、不活化ウイルス粒子またはウイルスサブユニットが含まれ、病気を引き起こすことなく免疫系を刺激します。遺伝子組換え帯状疱疹ワクチン（RZV）のような最新の帯状疱疹ワクチンは、強固な防御を提供し、旧来の製剤と比較して有効性が高いため好まれています。これらのワクチンは通常、数ヶ月の間隔をあけて2回接種することで、ウイルスに対する免疫が長期間持続します。

誰が帯状疱疹ワクチンを必要としているのでしょうか？

帯状疱疹ワクチンは、帯状疱疹やその合併症（帯状疱疹後神経痛（PHN）：帯状疱疹の発疹が治った後も、長く続く激しい痛みを特徴とする症状）を発症するリスクが高い50歳以上の成人や免疫力が低下している人に特に重要です。帯状疱疹は重大な不快感を引き起こし、日常生活に支障をきたし、重症の場合、発疹が目の近くに生じると視力喪失などの合併症を引き起こす可能性があるため、ワクチン接種は極めて重要です。高齢者の場合、加齢とともに感染と闘う免疫システムの能力が低下するため、ワクチン接種は帯状疱疹を予防する効果的な戦略となります。さらに、がん、HIV、免疫抑制療法を受けている人など、免疫系が低下している人には、帯状疱疹による衰弱のリスクを軽減するための予防策が帯状疱疹ワクチンに記載されています。公衆衛生機関は、高齢者の健康と生活の質を維持する役割を強調し、対象となる人々に対する定期的な予防医療の一環として帯状疱疹ワクチン接種を強く推奨しています。

帯状疱疹ワクチンの最新の革新と動向は？

帯状疱疹ワクチンの分野は、有効性、アクセシビリティ、患者のコンプライアンスを向上させることに焦点を当てた継続的な調査により、大きな進歩を遂げています。最も注目すべき動向の一つは、アジュバント化組換え帯状疱疹ワクチンのような組換えワクチンの開発であり、旧来の弱毒生ワクチンと比較して、より高い防御率とより長期の免疫持続を実現しています。このような組み換えワクチンは、生ワクチンが適さないような免疫不全患者にとって特に有利です。もう一つの動向は、一回の接種で帯状疱疹を含む複数の疾患を予防する混合ワクチンの利用可能性が高まっていることであり、これは予防接種プロセスを簡素化することで接種率を向上させることができます。さらに、自己免疫疾患の患者や臓器移植を受けている患者など、リスクのある若年層にもワクチン接種の推奨を拡大することへの関心が高まっています。さらに、より少ない接種回数で予防効果を発揮するワクチンや、より長期間の予防効果を発揮する改良型ワクチンの開発を目指した研究も進められています。このような技術革新により、帯状疱疹ワクチンはより効果的で利用しやすいものとなり、帯状疱疹の負担を軽減するための幅広い公衆衛生の取り組みに貢献しています。

帯状疱疹ワクチン市場の成長の原動力は？

帯状疱疹ワクチン市場の成長は、この痛みを伴い衰弱させる可能性のある症状の予防におけるワクチン接種の重要性が認識されつつあることを反映するいくつかの要因によって牽引されています。主な要因のひとつは、高齢化した世界人口が帯状疱疹やその合併症に罹患しやすくなっていることで、高齢者の間でワクチン接種の需要が高まっています。ワクチン開発における技術の進歩、特により効果的な組換えワクチンへのシフトも、より安全で信頼性の高い選択肢を幅広い患者に提供することで市場の成長を後押ししています。CDCやWHOなどの保健当局による公衆衛生の取り組みや推奨は、帯状疱疹ワクチンの採用を後押ししています。これらの機関は、帯状疱疹に関連する多大なヘルスケアコストや個人的苦痛を防ぐために定期的なワクチン接種を提唱しているからです。さらに、帯状疱疹後神経痛のような帯状疱疹の長期的影響に対する認識の高まりが、より多くの人々にワクチン接種を求めるよう促しています。新興市場におけるヘルスケアアクセスの拡大、ワクチン接種プログラムに対する政府支援の拡大も、世界の帯状疱疹ワクチンの需要増加に寄与しています。

調査対象企業の例（全35件）

  • Barinthus Biotherapeutics plc
  • CanSino Biologics Inc.
  • Chongqing Zhifei Biological Products Co., Ltd
  • CSL Seqirus
  • Curevo Inc.
  • Geneone Life Science
  • GSK plc
  • INVC Wellness Pvt. Ltd
  • Jiangsu Recbio Technology Co., Ltd
  • Merck & Co., Inc.
  • Pfizer inc
  • RxDx Healthcare
  • SK bioscience
  • SK chemicals

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP26774

Global Shingles Vaccines Market to Reach US$4.5 Billion by 2030

The global market for Shingles Vaccines estimated at US$3.2 Billion in the year 2023, is expected to reach US$4.5 Billion by 2030, growing at a CAGR of 5.0% over the analysis period 2023-2030. Recombinant Vaccines, one of the segments analyzed in the report, is expected to record a 5.1% CAGR and reach US$3.9 Billion by the end of the analysis period. Growth in the Live-Attenuated Vaccines segment is estimated at 4.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$868.6 Million While China is Forecast to Grow at 8.2% CAGR

The Shingles Vaccines market in the U.S. is estimated at US$868.6 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$928.2 Million by the year 2030 trailing a CAGR of 8.2% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.9% and 5.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.0% CAGR.

Global Shingles Vaccines Market - Key Trends and Drivers Summarized

How Do Shingles Vaccines Work and What Are Their Key Components?

Shingles vaccines are critical preventive tools designed to protect against herpes zoster, commonly known as shingles, a painful viral infection caused by the reactivation of the varicella-zoster virus—the same virus responsible for chickenpox. Once a person has had chickenpox, the virus remains dormant in the body, potentially reactivating later in life as shingles, particularly in older adults and those with weakened immune systems. Shingles vaccines work by boosting the body's immune response to the virus, thereby reducing the likelihood of reactivation and the severity of symptoms if an outbreak does occur. The key components of these vaccines include inactivated viral particles or viral subunits that stimulate the immune system without causing illness. Modern shingles vaccines, such as the recombinant zoster vaccine (RZV), provide robust protection and are preferred due to their higher efficacy compared to older formulations. These vaccines are typically administered in a series of two doses, spaced several months apart, ensuring long-lasting immunity against the virus.

Who Needs Shingles Vaccines and Why Are They So Important?

Shingles vaccines are particularly important for adults aged 50 and older, as well as individuals with weakened immune systems, who are at increased risk of developing shingles and its complications, such as postherpetic neuralgia (PHN), a condition characterized by severe, long-lasting pain even after the shingles rash has healed. Vaccination is crucial because shingles can lead to significant discomfort, interfere with daily activities, and in severe cases, result in complications like vision loss if the rash occurs near the eyes. For older adults, the immune system's ability to fight infections weakens with age, making vaccination an effective strategy to prevent shingles. Additionally, for individuals with conditions that compromise the immune system—such as cancer, HIV, or those on immunosuppressive therapies—shingles vaccines offer a proactive measure to mitigate the risk of a debilitating shingles outbreak. Public health organizations strongly recommend shingles vaccination as part of routine preventive care for eligible populations, emphasizing its role in maintaining health and quality of life in older adults.

What Are the Latest Innovations and Trends in Shingles Vaccines?

The field of shingles vaccines has seen significant advancements, with ongoing research focused on improving efficacy, accessibility, and patient compliance. One of the most notable trends is the development of recombinant vaccines, such as the adjuvanted recombinant zoster vaccine, which provides higher protection rates and longer-lasting immunity compared to the older live attenuated vaccines. These recombinant vaccines are particularly advantageous for immunocompromised individuals who may not be suitable candidates for live vaccines. Another trend is the increasing availability of combination vaccines that protect against multiple diseases, including shingles, in a single shot, which can improve vaccination rates by simplifying the immunization process. Additionally, there is growing interest in expanding vaccination recommendations to younger populations at risk, such as those with autoimmune diseases or those undergoing organ transplants. Furthermore, ongoing research aims to develop vaccines that provide protection with fewer doses or enhanced formulations that offer even longer protection. These innovations are making shingles vaccines more effective and accessible, contributing to broader public health efforts to reduce the burden of herpes zoster.

What Is Driving the Growth of the Shingles Vaccines Market?

The growth in the shingles vaccines market is driven by several factors that reflect the increasing recognition of the importance of vaccination in preventing this painful and potentially debilitating condition. One of the primary drivers is the aging global population, which is more susceptible to shingles and its complications, leading to a higher demand for vaccination among older adults. Technological advancements in vaccine development, particularly the shift towards more effective recombinant vaccines, are also fueling market growth by providing safer and more reliable options for a broader range of patients. Public health initiatives and recommendations from health authorities, such as the CDC and WHO, are propelling the adoption of shingles vaccines, as these organizations advocate for routine vaccination to prevent the significant healthcare costs and personal suffering associated with shingles. Additionally, increased awareness of the long-term effects of shingles, such as postherpetic neuralgia, is encouraging more individuals to seek vaccination. The expansion of healthcare access in emerging markets, along with growing government support for vaccination programs, is also contributing to the rising demand for shingles vaccines globally.

Select Competitors (Total 35 Featured) -

  • Barinthus Biotherapeutics plc
  • CanSino Biologics Inc.
  • Chongqing Zhifei Biological Products Co., Ltd
  • CSL Seqirus
  • Curevo Inc.
  • Geneone Life Science
  • GSK plc
  • INVC Wellness Pvt. Ltd
  • Jiangsu Recbio Technology Co., Ltd
  • Merck & Co., Inc.
  • Pfizer inc
  • RxDx Healthcare
  • SK bioscience
  • SK chemicals

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Shingles Vaccines - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Aging Population Propels Growth in Shingles Vaccines Market
    • Increased Awareness of Postherpetic Neuralgia Drives Adoption of Shingles Vaccines
    • Advancements in Vaccine Development Strengthen Business Case for Recombinant Shingles Vaccines
    • Expanding Immunization Guidelines Expands Addressable Market Opportunity for Shingles Vaccines
    • Rising Incidence of Immunocompromising Conditions Generates Demand for More Effective Shingles Vaccines
    • Growing Focus on Preventive Healthcare Spurs Growth in Shingles Vaccines Market
    • Vaccine Supply Chain Innovations Sustain Growth in Global Shingles Vaccination Efforts
    • Shift Towards Combination Vaccines Expands Market Potential for Shingles Vaccines
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Shingles Vaccines Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Shingles Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Shingles Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Shingles Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Recombinant Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Recombinant Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Recombinant Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Live-Attenuated Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Live-Attenuated Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Live-Attenuated Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Other Distribution Channels by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Shingles Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: USA 16-Year Perspective for Shingles Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Recombinant Vaccines and Live-Attenuated Vaccines for the Years 2014, 2024 & 2030
    • TABLE 23: USA Recent Past, Current & Future Analysis for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Shingles Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: Canada 16-Year Perspective for Shingles Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Recombinant Vaccines and Live-Attenuated Vaccines for the Years 2014, 2024 & 2030
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Shingles Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • JAPAN
    • Shingles Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: Japan 16-Year Perspective for Shingles Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Recombinant Vaccines and Live-Attenuated Vaccines for the Years 2014, 2024 & 2030
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Shingles Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • CHINA
    • Shingles Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: China 16-Year Perspective for Shingles Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Recombinant Vaccines and Live-Attenuated Vaccines for the Years 2014, 2024 & 2030
    • TABLE 41: China Recent Past, Current & Future Analysis for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: China 16-Year Perspective for Shingles Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • EUROPE
    • Shingles Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Shingles Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Shingles Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Europe 16-Year Perspective for Shingles Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Shingles Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Recombinant Vaccines and Live-Attenuated Vaccines for the Years 2014, 2024 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Shingles Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • FRANCE
    • Shingles Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 53: France Recent Past, Current & Future Analysis for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: France 16-Year Perspective for Shingles Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Recombinant Vaccines and Live-Attenuated Vaccines for the Years 2014, 2024 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: France 16-Year Perspective for Shingles Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • GERMANY
    • Shingles Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Germany 16-Year Perspective for Shingles Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Recombinant Vaccines and Live-Attenuated Vaccines for the Years 2014, 2024 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Shingles Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Italy 16-Year Perspective for Shingles Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Recombinant Vaccines and Live-Attenuated Vaccines for the Years 2014, 2024 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Shingles Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Shingles Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 71: UK Recent Past, Current & Future Analysis for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: UK 16-Year Perspective for Shingles Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Recombinant Vaccines and Live-Attenuated Vaccines for the Years 2014, 2024 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Shingles Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 77: Spain Recent Past, Current & Future Analysis for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Spain 16-Year Perspective for Shingles Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Recombinant Vaccines and Live-Attenuated Vaccines for the Years 2014, 2024 & 2030
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Spain 16-Year Perspective for Shingles Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 83: Russia Recent Past, Current & Future Analysis for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Russia 16-Year Perspective for Shingles Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Recombinant Vaccines and Live-Attenuated Vaccines for the Years 2014, 2024 & 2030
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Russia 16-Year Perspective for Shingles Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Rest of Europe 16-Year Perspective for Shingles Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Recombinant Vaccines and Live-Attenuated Vaccines for the Years 2014, 2024 & 2030
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for Shingles Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Shingles Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Shingles Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Shingles Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Asia-Pacific 16-Year Perspective for Shingles Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Shingles Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Recombinant Vaccines and Live-Attenuated Vaccines for the Years 2014, 2024 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Shingles Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Shingles Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 104: Australia Recent Past, Current & Future Analysis for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Australia 16-Year Perspective for Shingles Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Recombinant Vaccines and Live-Attenuated Vaccines for the Years 2014, 2024 & 2030
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Australia 16-Year Perspective for Shingles Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • INDIA
    • Shingles Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 110: India Recent Past, Current & Future Analysis for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: India Historic Review for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: India 16-Year Perspective for Shingles Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Recombinant Vaccines and Live-Attenuated Vaccines for the Years 2014, 2024 & 2030
    • TABLE 113: India Recent Past, Current & Future Analysis for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: India 16-Year Perspective for Shingles Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: South Korea 16-Year Perspective for Shingles Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Recombinant Vaccines and Live-Attenuated Vaccines for the Years 2014, 2024 & 2030
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: South Korea 16-Year Perspective for Shingles Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 16-Year Perspective for Shingles Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Recombinant Vaccines and Live-Attenuated Vaccines for the Years 2014, 2024 & 2030
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Shingles Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Shingles Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for Shingles Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for Shingles Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: Latin America 16-Year Perspective for Shingles Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Shingles Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Recombinant Vaccines and Live-Attenuated Vaccines for the Years 2014, 2024 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Shingles Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Argentina 16-Year Perspective for Shingles Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Recombinant Vaccines and Live-Attenuated Vaccines for the Years 2014, 2024 & 2030
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Argentina 16-Year Perspective for Shingles Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Brazil 16-Year Perspective for Shingles Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Recombinant Vaccines and Live-Attenuated Vaccines for the Years 2014, 2024 & 2030
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Brazil 16-Year Perspective for Shingles Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Mexico 16-Year Perspective for Shingles Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Recombinant Vaccines and Live-Attenuated Vaccines for the Years 2014, 2024 & 2030
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Mexico 16-Year Perspective for Shingles Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Rest of Latin America 16-Year Perspective for Shingles Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Recombinant Vaccines and Live-Attenuated Vaccines for the Years 2014, 2024 & 2030
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Rest of Latin America 16-Year Perspective for Shingles Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Shingles Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for Shingles Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for Shingles Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Middle East 16-Year Perspective for Shingles Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Shingles Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Recombinant Vaccines and Live-Attenuated Vaccines for the Years 2014, 2024 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Shingles Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 170: Iran Recent Past, Current & Future Analysis for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: Iran 16-Year Perspective for Shingles Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Recombinant Vaccines and Live-Attenuated Vaccines for the Years 2014, 2024 & 2030
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: Iran 16-Year Perspective for Shingles Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 176: Israel Recent Past, Current & Future Analysis for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: Israel 16-Year Perspective for Shingles Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Recombinant Vaccines and Live-Attenuated Vaccines for the Years 2014, 2024 & 2030
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: Israel 16-Year Perspective for Shingles Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: Saudi Arabia 16-Year Perspective for Shingles Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Recombinant Vaccines and Live-Attenuated Vaccines for the Years 2014, 2024 & 2030
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: Saudi Arabia 16-Year Perspective for Shingles Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 188: UAE Recent Past, Current & Future Analysis for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: UAE 16-Year Perspective for Shingles Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Recombinant Vaccines and Live-Attenuated Vaccines for the Years 2014, 2024 & 2030
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: UAE 16-Year Perspective for Shingles Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: Rest of Middle East 16-Year Perspective for Shingles Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Recombinant Vaccines and Live-Attenuated Vaccines for the Years 2014, 2024 & 2030
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: Rest of Middle East 16-Year Perspective for Shingles Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • AFRICA
    • Shingles Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 200: Africa Recent Past, Current & Future Analysis for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for Shingles Vaccines by Vaccine Type - Recombinant Vaccines and Live-Attenuated Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: Africa 16-Year Perspective for Shingles Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Recombinant Vaccines and Live-Attenuated Vaccines for the Years 2014, 2024 & 2030
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Shingles Vaccines by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: Africa 16-Year Perspective for Shingles Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030

IV. COMPETITION